Assisted Reproductive Technology

Assisted Reproductive Technology

Global Assisted Reproductive Technology Market to Reach US$27.6 Billion by 2030

The global market for Assisted Reproductive Technology estimated at US$19.7 Billion in the year 2023, is expected to reach US$27.6 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. In-Vitro Fertilization (IVF), one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$22.0 Billion by the end of the analysis period. Growth in the Frozen Embryo Replacement (FER) segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.3 Billion While China is Forecast to Grow at 4.8% CAGR

The Assisted Reproductive Technology market in the U.S. is estimated at US$5.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Assisted Reproductive Technology Market - Key Trends and Drivers Summarized

How Is Assisted Reproductive Technology Transforming Modern Fertility Treatments?

Assisted Reproductive Technology (ART) has revolutionized the field of fertility treatments, offering hope to millions of individuals and couples struggling with infertility. ART encompasses a range of medical procedures used to treat infertility, with in vitro fertilization (IVF) being the most well-known and widely used method. These technologies involve the manipulation of eggs, sperm, or embryos to achieve pregnancy, and have opened up new possibilities for those facing challenges in conceiving naturally. ART has advanced significantly since its inception, with improvements in techniques such as intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and egg freezing, which have dramatically increased success rates and expanded the options available to patients. As ART becomes more sophisticated, it continues to push the boundaries of what is possible in reproductive medicine, providing personalized solutions that cater to the unique needs of each patient.

What Technological Innovations Are Enhancing the Success Rates of ART?

Technological innovations have played a critical role in enhancing the success rates of Assisted Reproductive Technology, making these treatments more accessible and effective. Advances in embryo culture techniques, such as time-lapse imaging and the use of artificial intelligence (AI) to assess embryo quality, have improved the ability to select the most viable embryos for transfer, increasing the likelihood of a successful pregnancy. The development of more refined hormonal stimulation protocols has also reduced the risk of ovarian hyperstimulation syndrome (OHSS) and improved outcomes for patients undergoing IVF. Additionally, innovations in cryopreservation, particularly vitrification, have significantly improved the survival rates of frozen eggs and embryos, allowing for more flexible treatment schedules and better preservation of reproductive potential. These technological advancements are not only boosting success rates but also making ART a more reliable option for a broader range of patients, including those with complex infertility issues or those who wish to delay childbearing.

What Market Trends Are Driving the Adoption of Assisted Reproductive Technology?

Several key market trends are driving the adoption of Assisted Reproductive Technology, reflecting broader changes in societal attitudes towards family planning and advancements in reproductive medicine. The increasing trend towards delayed parenthood, driven by career priorities and changing social norms, has led to a growing demand for fertility preservation options such as egg freezing, which is now often included as part of ART services. Additionally, the rising awareness and acceptance of ART among same-sex couples and single parents have expanded the market for fertility treatments, as these groups seek options to build their families. The growth of medical tourism, particularly in countries where ART is more affordable or where certain treatments are more readily available, is also contributing to the global expansion of ART services. Furthermore, the ongoing trend towards personalized medicine is influencing the ART market, as patients increasingly seek tailored treatment plans that align with their specific needs and circumstances.

What Factors Are Driving the Growth of the Assisted Reproductive Technology Market?

The growth in the Assisted Reproductive Technology market is driven by several factors that are reshaping the landscape of fertility treatments. A primary driver is the increasing prevalence of infertility, influenced by factors such as delayed childbearing, lifestyle changes, and environmental factors that impact reproductive health. Technological advancements in ART, including improvements in embryo selection, cryopreservation, and genetic testing, are enhancing success rates and broadening the appeal of these treatments to a wider range of patients. The expansion of ART services in emerging markets, where access to fertility treatments is becoming more widespread, is also contributing to market growth. Additionally, the rise in demand for fertility preservation options, driven by trends such as delayed parenthood and the desire for family planning flexibility, is boosting the adoption of ART. As these factors continue to evolve, the ART market is expected to experience sustained growth, driven by innovation, changing societal norms, and the increasing need for effective fertility solutions.

Select Competitors (Total 11 Featured) -

• Bloom Fertility Centre
• Cosmos Biomedical Ltd.
• Cryolab Ltd.
• European Sperm Bank ApS
• Ferring Pharmaceuticals
• Irvine Scientific
• Microm UK Ltd
• ORIGIO A/S
• Ovascience Inc.
• Parallabs Limited

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.